Drug Profile
Lenalidomide companion diagnostic - Celgene/NanoString Technologies
Alternative Names: LymphMarkLatest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation; NanoString Technologies
- Developer Celgene Corporation
- Class 2 ring heterocyclic compounds; Antineoplastics; Diagnostic agents; Imides; Isoindoles; Piperidones; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Diffuse large B cell lymphoma
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 13 Aug 2019 Discontinued - Clinical-Phase-Unknown for Diffuse large B cell lymphoma (Diagnosis) in USA (unspecified route)
- 31 Jul 2019 NanoString Technologies and Celgene Corporation terminated their collaboration for development of Lenalidomide companion diagnostic